Your browser doesn't support javascript.
loading
Asthma Phenotyping in Primary Care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm Across All Asthma Severities.
Kerkhof, Marjan; Tran, Trung N; Allehebi, Riyad; Canonica, G Walter; Heaney, Liam G; Hew, Mark; Perez de Llano, Luis; Wechsler, Michael E; Bulathsinhala, Lakmini; Carter, Victoria A; Chaudhry, Isha; Eleangovan, Neva; Murray, Ruth B; Price, Chris A; Price, David B.
Afiliação
  • Kerkhof M; Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom.
  • Tran TN; AstraZeneca, Gaithersburg, Md.
  • Allehebi R; Department of Pulmonology, King Fahad Medical City, Riyadh, Saudi Arabia.
  • Canonica GW; Personalized Medicine Asthma and Allergy Clinic, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Heaney LG; UK Severe Asthma Network and National Registry Centre and Centre for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.
  • Hew M; Allergy, Asthma, and Clinical Immunology Service, Alfred Health, Melbourne, Australia; Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Perez de Llano L; Department of Respiratory Medicine, Hospital Universitario Lucus Augusti, Lugo, Spain.
  • Wechsler ME; NJH Cohen Family Asthma Institute, Department of Medicine, National Jewish Health, Denver, Colo.
  • Bulathsinhala L; Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom.
  • Carter VA; Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom.
  • Chaudhry I; Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom.
  • Eleangovan N; Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom.
  • Murray RB; Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom.
  • Price CA; Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom.
  • Price DB; Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care, Cambridge, United Kingdom; Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom. Electronic address: dprice@opri.sg.
J Allergy Clin Immunol Pract ; 9(12): 4353-4370, 2021 12.
Article em En | MEDLINE | ID: mdl-34403837
ABSTRACT

BACKGROUND:

We developed an eosinophil phenotype gradient algorithm and applied it to a large severe asthma cohort (International Severe Asthma Registry).

OBJECTIVE:

We sought to reapply this algorithm in a UK primary care asthma cohort, quantify the eosinophilic phenotype, and assess the relationship between the likelihood of an eosinophilic phenotype and asthma severity/health care resource use (HCRU).

METHODS:

Patients age 13 years and older with active asthma and blood eosinophil count or 1 or greater, who were included from the Optimum Patient Care Research Database and the Clinical Practice Research Datalink, were categorized according to the likelihood of eosinophilic phenotype using the International Severe Asthma Registry gradient eosinophilic algorithm. Patient demographic, clinical and HCRU characteristics were described for each phenotype.

RESULTS:

Of 241,006 patients, 50.3%, 22.2%, and 21.9% most likely (grade 3), likely (grade 2), and least likely (grade 1), respectively, had an eosinophilic phenotype, and 5.6% had a noneosinophilic phenotype (grade 0). Compared with patients with noneosinophilic asthma, those most likely to have an eosinophilic phenotype tended to have more comorbidities (percentage with Charlson comorbidity index of ≥2 28.2% vs 6.9%) and experienced more asthma attacks (percentage with one or more attack 24.8% vs 15.3%). These patients were also more likely to have asthma that was difficult to treat (31.1% vs 18.3%), to receive more intensive treatment (percentage on Global Initiative for Asthma 2020 step 4 or 5 44.2% vs 27.5%), and greater HCRU (eg, 10.8 vs 7.9 general practitioner all-cause consultations per year).

CONCLUSIONS:

The eosinophilic asthma phenotype predominates in primary care and is associated with greater asthma severity and HCRU. These patients may benefit from earlier and targeted asthma therapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Eosinófilos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adolescent / Humans Idioma: En Revista: J Allergy Clin Immunol Pract Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Asma / Eosinófilos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adolescent / Humans Idioma: En Revista: J Allergy Clin Immunol Pract Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido